Ovid Therapeutics (OVID) H.C. Wainwright 28th Annual Global Investment Conference summary

Strategic vision and approach

• Focus on developing novel, gentler medicines for brain conditions by targeting fundamental biological mechanisms of neural hyperexcitability.

• Emphasis on first-in-class and best-in-class therapies with broad therapeutic utility, aiming for step-change improvements for patients.

• Four to six proof-of-concept milestones expected over the next 6, 12, 18, and 24 months.

OV329 epilepsy program

• OV329 targets intractable epilepsies, including focal onset seizures and severe pediatric epilepsies like tuberous sclerosis complex and infantile spasms.

• Designed to inhibit the enzyme that degrades GABA, increasing inhibitory signaling in the brain.

• Demonstrated superior potency, safety, and tolerability compared to first-generation drugs, with no retinal toxicity observed.

• Phase II and photosensitivity studies are ongoing, with results expected in the coming months and a phase II readout in about a year.

• Commercial opportunity for OV329 exceeds $1 billion in focal onset seizures and $700 million in pediatric epilepsies.

KCC2 direct activator portfolio

• KCC2 is a neuron-specific target implicated in multiple CNS disorders, including schizophrenia, neuropathic pain, and epilepsy.

• First oral KCC2 direct activator is in phase I, with a ketamine challenge study planned before year-end and phase II in acute schizophrenia expected mid-next year.

• Preclinical and translational data show robust efficacy in psychoses, cognitive symptoms, and behavioral domains, outperforming current best-in-class drugs.

• KCC2 activation offers precise modulation without sedation, restoring normal physiological behavior in animal models.

• The program is positioned as a potential franchise with broad applications and significant commercial potential.